---

Highlights of Deals in February – 2026

 

Acquisitions:

1.     GSK to acquire 35Pharma in US$950 Million deal for cardiovascular drug.

2.     Alkem Labs unit to buy up to 55% of Occlutech for US$118 Million.

3.     Devyser acquires Swedish company Cybergene AB and strengthens its position in the aneuploidy market. The total purchase consideration amounts to US$1.31 Million.

 

Licensing:

1.     Kashiv BioSciences and Intas Pharma ink exclusive licensing and supply agreement for complex peptide product in Europe, UK & India.

2.     Lupin Signs License and Supply Agreement with Spektus to Commercialize Novel Antidepressant DeslaFlex™ in Canada.

3.     Eris Lifesciences partners Natco Pharma to commercialise Semaglutide in India.

4.     Organon pays US$27.5 Million upfront to license Sebela's hormone-free copper IUD.

5.     Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for US$205 Million.

6.     Chugai Pharma and Araris Biotech ink license agreement for Araris' linker-payload ADC technology AraLinQ.

7.     SanegeneBio licenses RNAi candidate to Genentech for US$200 Million upfront.

Investments/Fund Raising:

1.     Altesa BioSciences closes US$75 Million Series B financing.

2.     Pandorum Tech raises US$18 Million in series B funding to scale tissue regenerative therapies.

3.     Neogap secures US$9.37 Million to advance its personalized immunotherapy.

 

Co-Development:

1.     Syngene collaborates with Johns Hopkins University to advance early-stage drug discovery.

2.     Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues.

3.     Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development.

 

Aagami Updates:

1.     Contract Extension: Aagami has secured a contract extension a US client for divestment of a clinical NCE package.

2.     New Collaboration: Aagami has partnered with a reputed company for helping companies raise capital efficiently with a hybrid approach including Reg CF platforms.

3.     Aagami completed a productive Biotechgate partnering week (Feb23-27). It has opened up new horizons for Aagami and its world-wide clients.

4.     Upcoming: DCAT Week 2026: Our CEO will be in New York City for DCAT Week from March 23–26, 2026. A limited number of meeting slots are still available; we encourage you to submit your meeting request soon.

5.     Upcoming: Aagami will also be participating in ChinaBio® in Shanghai on April 28–29, 2026, as part of our ongoing commitment to global partnering.

Select opportunities available with us:

For Partnering/Licensing/ Co-development:

1. Seeking Licensing / Distribution Partners: Marketed Povidone-Iodine Nasal Spray (Nasodine®), patented, clinically proven to eliminate respiratory viruses and bacteria, offering safe and effective relief from cold, flu, and nasal congestion. Commercially launched in Singapore (2024) as an antiseptic liquid, with all government hospitals adoption and strong retail traction; Offering an attractive ready-to-launch Consumer wellness OTC opportunity in multiple markets (except Singapore, Brunei, Malaysia and the Philippines where already partnered).

2.     Seeking Co-development Partner/Investor/EPO supplier for Phase 3 stage Erythropoietin (EPO) patented asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach).  By using the 351(A) dossier, an easy and quick path via 351 (K) Biosimilar approval for multiple indications may also be obtained.

3.     Seeking Co-development/Out-Licensing: Phase 3 stage small molecule first-in-class eye drop to treat pre-surgical cataract (typically for patients 40 to 72 years of age).

4. Seeking Partnering/Co-development : Uncoupling Metastasis and Proliferation with translational platform, using Machine Learning and known molecules to disrupt cancer treatment. Lead asset (Phase 2) and platform, both available for licensing.

5.     Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses (RSV, FLU, COVID). Also, Phase 2 trials are starting in Central Africa for MPOX. Very effective in Bird Flu and Measles too.

6.     Smart Polymeric best-in-class delivery system platform with long-acting injectables pipeline. Seeking partnering and investment.

7.     Dental gel (Marketed in the US & approved in EU) for Prevention & Treatment of Periodontitis, Gingivitis, & Caries. Featured in WSJ, FOX, NBC, ABC, GQ. Already a profit-making product. Licensing available.

 

For Acquisition:

1.    [URGENT] Lucrative Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic. An offer is in finalization stage.

2.    Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc. - for Next-generation biologics.

3.    A High Multiple ROI by acquiring small molecule clinical asset in rare diseases (sickle cell disease & thalassemia). (Two Phase 1 completed. Phase 2 ready). Low cost and quicker to market vs. Gene Therapy. Their previous asset was acquired for US$400 million.

For Investment:

1.     High ROI Opportunity to Invest in U.S.based medtech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform (On the market for 4 years). Exit via an IPO, strategic M&A, or private equity buyout.

2. Seeking US $3 to 10 Million: Uncoupling Metastasis and Proliferation with translational platform, using Machine Learning and known molecules to disrupt cancer treatment. The funds will be used to progress the pipeline to the out-licensing stage.
3. Seeking Investment: Revolutionizing oncology with patented smart drug delivery platform that enhances chemotherapy efficacy while minimizing toxic side effects. Backed by US$14 million in funding and a team with 7 prior drug launches, client is advancing a pipeline of 5 chemotherapies toward IND. Targeting a US$180 billion+ oncology market.

Hope you found the content useful. We welcome your feedback and queries.